Biocardia announces reverse stock split

Sunnyvale, calif., may 21, 2024 (globe newswire) -- biocardia, inc. [nasdaq: bcda], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that, following approval by the company's stockholders and its board of directors, the company intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 15 pre-split shares. the reverse stock split will become effective at 12:01 a.m. eastern daylight time on thursday, may 30, 2024. the company's common stock will begin trading on a split-adjusted basis when the market opens on thursday, may 30, 2024. the company's common stock and warrants will continue to be traded on the nasdaq capital market under the ticker symbols “bcda” and “bcdaw,” respectively. the reverse stock split is intended to increase the minimum bid price requirement for continued listing on the nasdaq capital market. the company, however, cannot assure that the price of its common stock after the reverse stock split will reflect the corresponding split ratio, that the price per share following the effective time will be maintained for any period of time, or that the price will remain above the pre-split trading price.
BCDA Ratings Summary
BCDA Quant Ranking